Tempus Labs has filed a patent for novel organoid culture media and systems, along with methods for culturing tumor organoids. The patent also covers tumor organoids developed using these systems, methods for assessing their clonal diversity, and their use in tumor modeling and drug development. Notably, the organoid culture media is free of R-spondins. GlobalData’s report on Tempus Labs gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Tempus Labs Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Tempus Labs, personalized treatment planning was a key innovation area identified from patents. Tempus Labs's grant share as of September 2023 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Novel organoid culture media for tumor organoids

Source: United States Patent and Trademark Office (USPTO). Credit: Tempus Labs Inc

A recently filed patent (Publication Number: US20230272489A1) describes a method for culturing tumor organoids and evaluating their genomic profiles. The method involves culturing tumor organoids derived from tumor samples in an organoid culture medium with low levels of R-spondins. The genomic variant profiles of the tumor organoids are compared to a reference genomic variant profile obtained from the tumor sample. The goal is to confirm a high concordance in the clonal diversity between the tumor organoids and the tumor sample.

The method can be applied to tumor samples from various types of cancers, including anal cancer, basal cell skin cancer, squamous cancer, breast cancer, bladder cancer, cervical cancer, endometrial cancer, head and neck cancer, hepatobiliary cancer, kidney cancer, gastric cancer, lung cancer, mesothelial cancer of the pleural cavity, mesothelial cancer of the peritoneal cavity, ovarian cancer, and prostate cancer.

The organoid culture medium used in the method may contain growth factors such as Noggin, EGF, FGF7, and FGF10. Additionally, molecular inhibitors like Rho kinase inhibitor, transforming growth factor-beta inhibitor, and MAP kinase inhibitor may be included in the medium.

The method also includes the option of exposing the tumor organoids to a therapeutic agent and evaluating the genomic variant profile of the exposed tumor organoid cell line. This evaluation can help determine the effect of the therapeutic agent on the tumor organoids and identify any changes in the genomic variants.

Based on the evaluation of the genomic profiles, the method can assist in assigning appropriate therapies to patients based on the properties of their tumor organoids.

In summary, the filed patent describes a method for culturing tumor organoids and comparing their genomic profiles to tumor samples. The method allows for the evaluation of clonal diversity and can be used to assess the effects of therapeutic agents on tumor organoids. This method has potential applications in personalized medicine and treatment selection for various types of cancers.

To know more about GlobalData’s detailed insights on Tempus Labs, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies